CARGO Therapeutics, Inc., established in 2019 and headquartered in San Mateo, California, operates within the biotechnology sector, specifically focusing on developing chimeric antigen receptor (CAR) T-cell therapies aimed at treating cancer. Their lead program includes CRG-022, an autologous CD22 CAR T-cell product candidate designed for phase 2 trials to target CD22, an alternative tumor antigen present in B-cell malignancies. This program exemplifies CARGO's commitment to advancing the next generation of potentially curative cell therapies for cancer patients. The company was originally known as Syncopation Life Sciences, Inc. before rebranding to CARGO Therapeutics, Inc. in September 2022. The founders of CARGO Therapeutics are a group of internationally recognized experts from Stanford University and a prominent cancer advocate, including Dr. Crystal L. Mackall, Dr. Robbie Majzner, Nancy Goodman, J.D., and Dr. Louai Labanieh, highlighting a strong foundation in immuno-oncology and the engineering of novel CAR T-cells​